OVERVIEWPlease join us Wednesday February 27th at 10AM ET as we review the pharmaceutical industry's testimony before the Senate Finance Committee against the backdrop of proposed changes to manufacturer drug rebates. We will explore areas of agreement between the pharmaceutical industry's witnesses and the Trump Administration's proposed rule and what differences exist with Senate Democrats. Given areas of agreement, we will consider the realistic legislative initiatives that may develop in the coming months and how those might affect administration policy. We will evaluate likely outcomes, timing and impact on pharmacy benefit managers like CVS, insurers like UNH, ANTM, CI and HUM and the manufacturers like ABBV, MNK. CLICK HERE for event details (includes video link, materials link and dial-in).
|
Drug prices are a top priority on both sides of Capitol Hill and at the White House. Despite the divided government, there is broad agreement that action must be taken. The Senate Finance Committee held one hearing in January to which they invited executives from seven pharmaceutical companies. All declined to attend, to the great displeasure of Chairman Chuck Grassley and Ranking Member Ron Wyden. Another invitation was issued, this one with the thinly veiled threat of subpeona, which was all the inspiration executives from ABBV, AZN, BMY, JNJ, MRK, PFE needed to accept an invitation to today's hearing.
We will explore major themes from the hearing like the need to address patent thickets, expanding the rebate safe harbor changes to apply to commercial plans, price disparity with OECD countries, a need for greater transparency, supply chain impacts and price negotiation in Part B. We will spend a few extra minutes on ABBV's testimony which was certainly a head scratcher in places. Finally, we will explore whether Part D plan sponsors can raise premiums as they claim in the face of elimination of safe harbor for rebates.
Please join us.
Emily Evans
Managing Director – Health Policy
Twitter
LinkedIn
